SL-172154

N/A

Report date: 2026/03/19 20:00:18

Base Information

Drug NameSL-172154
Drug Alias NameSL-172154SIRPα -Fc-CD40L
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionCluster of differentiation 47 inhibitorsTumor necrosis factor receptor superfamily member 5 agonists
TargetsCluster of differentiation 47Tumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsMyelodysplastic SyndromesFallopian Tube NeoplasmsOvarian Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesShattuck Labs Inc
China Registration ClassN/A

Develop Information

Active CompaniesShattuck Labs Inc
Inactive CompaniesN/A
Active IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms +[4] 
Inactive IndicationsMyelodysplastic SyndromesSquamous Cell Carcinoma of Head and NeckCarcinoma, Squamous Cell +[4] 

Other Information

ATC CodeN/A
Related LinksN/A